Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

ENSAT Stage I Adrenal Cortex Carcinoma 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 1280Specimen Handling 928Carboplatin 836Magnetic Resonance Spectroscopy 831Cyclophosphamide 807Cisplatin 735Nivolumab 679Paclitaxel 634Radiotherapy 617Gemcitabine 579Biopsy 560Bevacizumab 486Dexamethasone 444fludarabine 409Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 363Fluorouracil 358atezolizumab 353durvalumab 339Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 320Blood Specimen Collection 315Standard of Care 311Pemetrexed 308Ipilimumab 303Radiation 289

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mitotane × 1 year × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡